October | 2014 |

October 27, 2014
by PharmaReviews
0 comments

October 16, 2014
by PharmaReviews
0 comments

October 9, 2014
by PharmaReviews
1 Comment

October 5, 2014
by PharmaReviews
0 comments

Oxidized LDL might actually be ‘good guy’

A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a “bad guy” in the development of heart disease and other conditions. Jason Meyer, a University of … Continue reading →

October 5, 2014
by PharmaReviews
0 comments

Transplant drug could boost the power of brain tumor treatments

Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the … Continue reading →

October 5, 2014
by PharmaReviews
1 Comment

New research outlines promising therapies for small cell lung cancer

Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no … Continue reading →

October 5, 2014
by PharmaReviews
0 comments

Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study

Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved … Continue reading →

October 5, 2014
by PharmaReviews
0 comments

Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion

Bayer has completed the acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co., Inc., Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals. “This acquisition is a … Continue reading →